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OBJECTIVES: Major bleeding in acute coronary syndrome
(ACS) patients has a signiﬁcant impact on clinical outcomes. The
economic costs associated with these events have not been
assessed. This study was undertaken to estimate the costs asso-
ciated with manage major bleeds in ACS patients in the hospital
setting METHODS: A retrospective chart review was undertaken
in a French hospital to identify ACS patients with the following
bleeding events: intracranial haemorrhage (ICH), retroperitoneal
(RP) gastrointestinal (GI), puncture site or excessive surgical
bleeds (PSB), blood transfusion requiring 2 or more units, or
decrease in Hb > 3g/dL (DHb). Patient age, reason for admission,
extended length of stay (LOS) attributed to the bleed, ward type,
and resources to manage the bleed were collected. RESULTS: 48
cases were analysed, 52% were males, with an average age of
72.5 years. The reasons for hospital admission were 39.6% non
ST-segment Elevation Myocardial Infarction (NSTEMI), 43.8%
ST-segment Elevation MI (STEMI) and 10.4% unstable angina
(UA). The distribution of hemorrhagic events were 40.4% DHb,
27.7% transfusions, 21% PSB, 8.5% GI and 2.1% RP bleeds.
The mean length of stay (LOS) was 8.5 days across all patients.
Extended 6.5 day mean LOS (76% of total stay) was found for
20 patients. The number of extra days varied by type of bleed.
80% of PSB patients had extended stays compared to 50% of GI
bleed, 38% of transfusion and 21% DHb patients. Ultrasound
was the most common additional procedure followed by endos-
copy. Applying unit costs from France for procedures, transfu-
sions, and extended LOS resulted in additional costs of €1709 for
DHb, €3245 for transfusions, €2116 for GI, €4091 for RT and
€6585 for PSB. CONCLUSION: Hospitalised ACS patients with
bleeding complications have increased mean resource use and
41% have extended LOS leading to an estimated additional
average €3185 for the hospital stay.
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OBJECTIVES: The Norwegian Government changed the reim-
bursement criteria for statins June 1, 2005. Simvastatin was
deemed ﬁrst-line statin except when otherwise medically justi-
ﬁed. Further, eligible treated patients were to be switched from
atorvastatin to simvastatin within one year, with recommenda-
tions to double the mg dose. The objective of this analysis was
to estimate the: 1) impact of statin on lipid control and CV
events, and 2) cost effectiveness of non-switching vs switching
in statin therapy. METHODS: Prescription data were obtained
from a Norwegian Institute of Public Health report of national
pharmacy prescription registry data. Average reduction in total
cholesterol was estimated based on dose distribution of atorv-
astatin pre-switch and simvastatin post-switch according to
product labeling. CV events, costs, and QALYs were estimated
from a lifetime Markov model applying Framingham risk
equations and Norwegian epidemiologic data, assuming a
primary prevention population. Event costs were based on
Norway DRG costs; drug costs on current and future treatment
costs, assuming two years to generic atorvastatin. Discounting
was 3% per annum. RESULTS: Following June 1, 2005,
50,616 patients were identiﬁed who switched from atorvastatin
to simvastatin; 38% to a lower potency dose. Dose distribution
for atorvastatin was 40.4%/44.4%/12.6%/2.5% for 10/20/40/
80 mg, respectively. Post-switch simvastatin distribution was
9.4%/45.4%/39.9%/5.2% for 10/20/40/80 mg, with an esti-
mated 8.6% absolute loss in total cholesterol reduction. This
could lead to 30 additional CV events per 1000 patients, and
0.12 QALYs lost. The incremental cost effectiveness ratio for
non-switching versus the switching policy is estimated to be
€8526 per QALY saved. CONCLUSION: Following the policy
in Norway, a considerable portion of patients were switched to
a simvastatin dose with lower cholesterol lowering effect and a
consequent increased CV risk. Maintaining patients on estab-
lished statin therapy may have been a more cost-effective
approach in this setting.
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OBJECTIVES: To assess the attitudes and beliefs of physi-
cians about hypercholesterolemia and its treatment in Spain.
METHODS: An observational, cross-sectional questionnaire
survey was performed in 2006. 22 cardiologists, 23 endocri-
nologists, 22 internists and 21 primary care physicians were
included. Their attitudes and beliefs about hypercholester-
olemia and its treatment were assessed by means of 7-items
Likert scales and ordinal categorical variables. RESULTS:
Eighty-eight physicians were included in the study, 77% were
over 40 years of age and mainly working in urban areas (82%).
A total of 97.7% agreed that national guidelines and target
levels for LDL-c management are clear, and 11.5% considered
they are difﬁcult to apply due to the frequent changes in the
LDL-c target level. A total of 48.2% agreed that statin mono-
therapy is sufﬁcient to make most of patients get to LDL-c goal
and, for patients not reaching LDL-c goal, 82.7% agreed they
would consider trying a combination therapy, 81% increasing
the statin dose, and 21.7% switching to another statin. When
they were asked to state the most frequent reason that made
patients with lipid-lowering therapy not getting to cholesterol
goal, 60.2% referred to the patient’s lack of compliance,
35.2% to the lack of compliance with diet/exercise, and 31.8%
to the insufﬁcient dose or efﬁcacy of pharmacologic therapy. A
total of 63.2% agreed that compliance is reduced because
patients take too many drugs, and 97.7% agreed that ﬁxed
dose of combination therapies would increase patient compli-
ance. CONCLUSION: Despite the high degree of knowledge
about the recommendations for LDL-c target levels among phy-
sicians and the limited additional efﬁcacy obtained by titrating
the statin dose, over half of physicians believe that statin mono-
therapy is enough to achieve LDL-c target levels, and mainly
attribute to the patient’s lack of compliance the low proportion
of patients achieving LDL-c target levels.
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